StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) company profile

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3099% above fair value
$167.58−0.50 (-0.30%)

Close on Nov 16, 2026Market cap $207.86BP/E –Yield 1.89%

About Gilead Sciences

Biological Products, (No Diagnostic Substances), SIC 2836

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and delivers therapies targeting life-threatening medical conditions. The firm concentrates its commercial and clinical efforts primarily on virology, oncology, and liver diseases. Its portfolio comprises treatments for HIV management and prevention, hepatitis, COVID-19, and several cancers, as well as specialized cell therapies and antifungal solutions. Gilead provides these medicines to patients globally, commercializing them mainly through pharmaceutical wholesale distributors, specialty distributors, direct clinical promotion to healthcare providers, and regional commercial partnerships.

The company operates marketing subsidiaries and commercial sales infrastructure in more than 35 countries worldwide, with corporate headquarters located in Foster City, California. Gilead supports its international drug pipeline and supply chain through owned and leased facilities located across the United States, Ireland, Canada, and the Netherlands, which perform research, processing, packaging, and manufacturing. As of late 2025, the enterprise employs approximately 17,000 individuals across its global business operations.

Summary of the business section of Gilead Sciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Gilead Sciences, Inc.
Founded
1987
Headquarters
Foster City, CA
Address
333 Lakeside Dr 94404
Phone
(650) 574-3000
Website
gilead.com
Employees
17,000, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
GILD
Exchange
Nasdaq
IPO date
Jan 22, 1992
Shares outstanding
1.24B, Oct 23, 2026
Public float
$103.20B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Jan 28, 2013; 2-for-1, Jun 25, 2007; 2-for-1, Sep 7, 2004; 2-for-1, Mar 8, 2002; 2-for-1, Feb 22, 2001
SEC CIK
882095
CUSIP
375558103
ISIN
US3755581036
FIGI
BBG000CKGBP2
Share class FIGI
BBG001S6Y1X7
LEI
549300WTZWR07K8MNV44
EIN
94-3047598

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Daniel Patrick O'DayChairman & CEO, Director551,683
Wettan Keeley M. CainEVP Gen Counsel, Legal & Comp5,360
Andrew D. DickinsonChief Financial Officer161,096
Johanna MercierChief Comm & Corp Aff Officer113,684
Erin BurkhartSVP, Controllership2,223
Dietmar BergerChief Medical Officer19,785
Deborah H. TelmanEVP, Corporate Affairs & GC79,641
Diane E. WilfongInterim Corp Controller & CAO46,597
Sandra PattersonSVP, Controllership40,077
Merdad ParseyChief Medical Officer84,621
Kelly A. KramerDirector1,339
Anthony WeltersDirector20,612
Jeffrey BluestoneDirector10,066
Jacqueline K. BartonDirector27,202
Javier RodriguezDirector13,364
Sandra HorningDirector6,293
Ted W. LoveDirector5,484
Harish ManwaniDirector15,015

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$28.44M$63.26M$9.25M$255$125
FY2024$23.69M$44.79M$7.73M$187$93
FY2023$22.61M$15.48M$7.59M$157$94
FY2022$21.62M$54.97M$7.87M$161$90
FY2021$19.23M$31.49M$6.28M$130$100
FY2020$19.00M$16.12M$6.62M$93$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Daniel P. O’Day
Chairman and Chief Executive Officer
$1.80M–$15.24M$4.50M$4.85M$2.06M$28.44M+20%
Andrew D. Dickinson
Chief Financial Officer
$1.12M–$4.32M$1.30M$1.96M$70.98K$8.77M+8%
Johanna Mercier
Chief Commercial and Corporate Affairs Officer
$1.18M–$4.56M$1.30M$2.15M$102.98K$9.30M+8%
Dietmar Berger, M.D., Ph.D.
Chief Medical Officer
$969.23K$3.00M$7.00M$1.00M$1.60M$350.25K$13.92M–
Deborah H. Telman
Former Executive Vice President, Corporate Affairs and General Counsel
$977.33K–$3.07M$900.07K–$55.48K$5.00M-18%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, Gilead had approximately 17,000 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?